›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:OncoDEEP
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
OncoDNAType:
Laboratory Developed Test
Related tests:
OncoDEEP analyses solid biopsies by combining next-generation sequencing (313 genes), IHCs to study protein expression and additional tests. This complete tumour profiling allows to predict patient response to approved or experimental hormonal therapies, targeted drugs, immunotherapies and chemotherapies. The NGS panel is accurately designed according to oncologists’ needs in their current practice. Importantly, it includes an accurate determination of MSI, TMB and LOH. The NGS panel is regularly updated based on new findings reported in the literature in order to provide patients with the most cost-effective solution. NRTK testing is included in OncoDEEP for some cancer types and it can be ordered also as a standalone test.
Cancer:
Breast Cancer, Colorectal Cancer, Glioblastoma, Lung Adenocarcinoma, Non Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Triple Negative Breast Cancer, Urothelial Cancer
Gene:
ALK (Anaplastic lymphoma kinase), ARID1A (AT-rich interaction domain 1A), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), EGFR (Epidermal growth factor receptor)
See More ...
ALK (Anaplastic lymphoma kinase), ARID1A (AT-rich interaction domain 1A), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), EGFR (Epidermal growth factor receptor), ER (Estrogen receptor), ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3), ERBB4 (erb-b2 receptor tyrosine kinase 4), ERCC1 (Excision repair cross-complementation group 1), FGFR (Fibroblast Growth Factor Receptor), HER-2 (Human epidermal growth factor receptor 2), KRAS (KRAS proto-oncogene GTPase), MLH1 (MutL homolog 1), MSI (Microsatellite instability), NRAS (Neuroblastoma RAS viral oncogene homolog), NTRK (Neurotrophic receptor tyrosine kinase), NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1), NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2), NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3), PD-L1 (Programmed death ligand 1), PD-L2 (Programmed Cell Death 1 Ligand 2), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), PTEN (Phosphatase and tensin homolog), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), RRM1 (Ribonucleotide Reductase Catalytic Subunit M1), TMB (Tumor Mutational Burden), TOP2A (DNA topoisomerase 2-alpha), TUBB3 (Tubulin beta 3 class III)
Drug:
5-fluorouracil, Alecensa (alectinib), Alunbrig (brigatinib), Erbitux (cetuximab), Gavreto (pralsetinib), Gilotrif (afatinib), Herceptin (trastuzumab), Kadcyla (ado-trastuzumab emtansine), Keytruda (pembrolizumab), Libtayo (cemiplimab-rwlc), Lorbrena (lorlatinib), Lynparza (olaparib), Mekinist (trametinib), Nerlynx (neratinib), Opdivo (nivolumab), Pemazyre (pemigatinib), Perjeta (pertuzumab), Piqray (alpelisib), Retevmo (selpercatinib), Rozlytrek (entrectinib), Tabrecta (capmatinib), Tafinlar (dabrafenib), Tagrisso (osimertinib), Tecentriq (atezolizumab), Vitrakvi (larotrectinib), Xalkori (crizotinib), Zykadia (ceritinib), anastrozole, capecitabine, epirubicin, erlotinib, everolimus, exemestane, gefitinib, gemcitabine, lapatinib, letrozole, pemetrexed, tamoxifen
Method:
Next-Generation Sequencing (NGS)
